MEDI 3617

Drug Profile

MEDI 3617

Alternative Names: ANG-2 mAb; Anti-ANG-2 mAb; MEDI3617

Latest Information Update: 14 Dec 2015

Price : $50

At a glance

  • Originator MedImmune
  • Developer Dana-Farber Cancer Institute; MedImmune
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiopoietin-2 inhibitors; TIE 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Malignant melanoma; Solid tumours
  • Preclinical Rheumatoid arthritis

Most Recent Events

  • 08 Oct 2015 Phase-I development for Malignant melanoma (Inoperable/Unresectable, Combination therapy, Metastatic disease) is ongoing in USA (NCT02141542)
  • 04 Jun 2014 Interim adverse events and efficacy data from a phase I trial in Solid tumours presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO-2014)
  • 01 May 2014 Phase-I clinical trials in Malignant melanoma (Inoperable/Unresectable, Combination therapy, Metastatic disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top